Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2002
12/17/2002US6495145 LktA deletion mutant of P. haemolytica
12/17/2002US6495144 A peptide having substantial homology with the cbf1/rbpjk (cell binding factor-1/recombination bining protein j kappa) interaction domain of ebna2 comprising specific peptide containing 15-20 amino acids
12/17/2002US6495139 Identification and characterization of novel pneumococcal choline binding protein, CBPG, and diagnostic and therapeutic uses thereof
12/17/2002US6495138 PRRSV antigenic sites identifying peptide sequences of PRRS virus for use in vaccines or diagnostic assays
12/17/2002CA2080260C Monoclonal antibodies against tumor-associated antigens, processes for the preparation thereof and the use thereof
12/17/2002CA1341411C Method for producing fv fragments in eukaryotic cells
12/17/2002CA1341410C Recombinant acquired immune deficiency syndrome (aids) viral envelope protein and method of testing for aids
12/15/2002CA2390327A1 Method
12/12/2002WO2002099427A1 Srpks as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099426A1 Pecis as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099140A1 GLRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099138A2 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099125A1 PIBs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099122A1 Modifiers of the p53 pathway and methods of use
12/12/2002WO2002099116A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/12/2002WO2002099101A1 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes
12/12/2002WO2002099099A2 Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8 and their use in diagnostic and therapeutic applications
12/12/2002WO2002099097A1 Novel compounds for chemiluminescense procedures
12/12/2002WO2002099083A2 Gfats as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099075A2 Prmts as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099074A2 Slc7s as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099068A2 Lces as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099062A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
12/12/2002WO2002099060A2 Dgks as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099059A2 U5-200KDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099058A2 KCNMAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099057A2 Sams modifiers of the p53 pathway and methods of use
12/12/2002WO2002099056A2 C22c7orfs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099055A2 Cips as modifiers of the p53 pathway and method of use
12/12/2002WO2002099054A2 Hccss as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099053A2 Slc22as as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099052A2 Opns as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099051A2 Nits as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099050A2 Tprs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099049A2 Tbc1d1s as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099048A2 LIMKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099047A2 PROMLs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099046A2 Spo11 as modifier of the p53 pathway and methods of use
12/12/2002WO2002099044A2 B3galts as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099042A2 Cads as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099041A2 Ces2s as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099040A2 Igs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099039A2 Peptides for chlamydophila pneumoniae vaccine and diagnosis
12/12/2002WO2002099038A2 Adsls as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099036A2 Inhibition of neurodegeneration
12/12/2002WO2002098920A1 Molecules and methods for inhibiting shedding of kim-1
12/12/2002WO2002098909A1 Vaccines
12/12/2002WO2002098900A2 Novel human proteins, polynucleotides encoding them and methods of using the same
12/12/2002WO2002098899A2 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098898A2 FLJs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098897A2 Modified antibodies to prostate-specific membrane antigen and uses thereof
12/12/2002WO2002098891A2 GADs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098890A2 MARKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098889A2 MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098468A1 SLC13As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098467A1 Slc2as as modifiers of the p53 pathway and methods of use
12/12/2002WO2002098466A1 Replicating adenovirus vectors
12/12/2002WO2002098460A1 Compositions and methods for treating hyperimmune response in the eye
12/12/2002WO2002098459A2 USE OF IgM ANTIBODIES AGAINST dsDNA IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS
12/12/2002WO2002098456A2 Antigens and vectors for vaccination
12/12/2002WO2002098446A1 Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
12/12/2002WO2002098443A2 Stabilised mrna with an increased g/c content and optimised codon for use in gene therapy
12/12/2002WO2002098424A1 Novel anti-infectives
12/12/2002WO2002098370A2 Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
12/12/2002WO2002098369A2 Mutant forms of cholera holotoxin as an adjuvant
12/12/2002WO2002098368A2 Mutant forms of cholera holotoxin as an adjuvant
12/12/2002WO2002098362A2 Use of rank antagonists to treat cancer
12/12/2002WO2002098360A2 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
12/12/2002WO2002098359A2 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
12/12/2002WO2002098356A2 Ppp2cs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002098346A2 Method and pharmaceutical composition for the treatment of multiple sclerosis
12/12/2002WO2002089805A3 Use of regularly scheduled high dose intravenous methotrexate therapy
12/12/2002WO2002086058A9 Method for producing catalytic antibodies (variants), antigens for immunisation and nucleotide sequence
12/12/2002WO2002083879A3 Immunotherapy based on dendritic cells
12/12/2002WO2002082044A3 Method of imaging cell death in vivo
12/12/2002WO2002076494A3 USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
12/12/2002WO2002074798A3 The genome of a bifidobacterium
12/12/2002WO2002072015A3 M cell directed vaccines
12/12/2002WO2002070552A3 POLYPEPTIDE FROM A HDM2 PROTEIN SPECIFIC MURINE Α/β T-CELL RECEPTORS, NUCLEIC ACIDS CODING FOR THE ABOVE AND USE THEREOF
12/12/2002WO2002067984A3 Materials and methods for detecting, preventing, and treating hiv and fiv retroviral infection
12/12/2002WO2002067848A3 PEPTIDES FROM THE 16/6id ANTIBODY FOR TREATING SLE
12/12/2002WO2002064161A3 Method and compositions for immunization with the pseudomonas v antigen
12/12/2002WO2002062972A3 Hybridoma cell line g250 and its use for producing monoclonal antibodies
12/12/2002WO2002061113A3 Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
12/12/2002WO2002058534A3 Compositions and methods for the therapy and diagnosis of colon cancer
12/12/2002WO2002053288A3 A method for the manufacture of compositions containing low concentrations of salts
12/12/2002WO2002045742A3 Lipoteichoic acid immunogenic compositions and methods of making and using thereof
12/12/2002WO2002044718A3 S.aureus protein staau r2, gene encoding it and uses thereof
12/12/2002WO2002032942A3 Compositions and methods for modulating rsv infection and immunity
12/12/2002WO2002026784A3 Matrix proteins m1 and m2 of infections salmon anaemia virus
12/12/2002WO2002018593A3 Modulation of fas and fasl expression
12/12/2002WO2002018557A3 Human kinases
12/12/2002WO2002008292A3 Human monoclonal antibody against hepatitis c virus e2 glycoprotein
12/12/2002WO2002004017A3 Method for preparing oral vaccines
12/12/2002WO2002002775A3 Calpain protease 12
12/12/2002WO2001097850A3 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
12/12/2002WO2001089568A9 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
12/12/2002WO2001038360A9 Novel hcv non-structural polypeptide
12/12/2002WO2001018207A9 Human 7tm proteins receptors and polynucleotides encoding the same
12/12/2002WO2001012816A9 Porcine endovirus gag and env and diagnostic uses thereof
1 ... 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 ... 1823